Related Experiment Video

Updated: Aug 14, 2026

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

Therapeutic potential of the anti-angiogenesis drug TNP-470

P Gervaz1, C Fontolliet

  • 1Department of Surgical Research, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.

International Journal of Experimental Pathology
|May 13, 1999
PubMed

Insights

Tumour growth requires new blood vessels. TNP-470 is an anti-angiogenic drug showing promise in clinical trials for treating neoplasms by inhibiting tumour neovascularization.

Area of Science:

  • Oncology
  • Vascular Biology
  • Pharmacology

Background:

  • Neovascularization is essential for tumor expansion and metastasis.
  • Inhibiting angiogenesis is a key strategy in anti-cancer therapy.
  • Anti-angiogenic drugs are advancing into clinical applications for neoplasms.

Purpose of the Study:

  • To review experimental and clinical data on TNP-470.
  • To evaluate the role of TNP-470 in anti-tumour treatment.
  • To assess the efficacy of TNP-470 as an angiogenesis inhibitor.

Main Methods:

  • Literature review of experimental studies.
  • Analysis of clinical trial data.
  • Evaluation of TNP-470's anti-angiogenic effects.

Main Results:

  • TNP-470 demonstrates significant anti-angiogenic properties.
  • Experimental data support TNP-470's role in inhibiting tumour growth.
  • Clinical trials provide evidence for TNP-470's therapeutic potential.

Conclusions:

  • TNP-470 is a promising agent for anti-neoplastic therapy.
  • Inhibition of angiogenesis with TNP-470 warrants further clinical investigation.
  • TNP-470 represents a viable strategy in the fight against cancer.

More Related Videos

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo08:19

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Published on: July 20, 2019

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research08:53

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research

Published on: September 16, 2019

Related Concept Videos

Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...